Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium

References

• Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341(21):1565–1571.
   PubMed Web of Science ®Google Scholar
• Weber DM, Chen C, Niesvizky R, et al.; Multiple Myeloma Study Investigators. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med. 2007;357(21):2133–2142.
   PubMed Web of Science ®Google Scholar
• Dimopoulos M, Spencer A, Attal M, et al.; Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med. 2007;357(21):2123–2132.
   PubMed Web of Science ®Google Scholar
• Hulin C, Belch A, Shustik C, et al. Updated outcomes and impact of age with lenalidomide and low-dose dexamethasone or melphalan, prednisone, and thalidomide in the randomized, phase III FIRST Trial. J Clin Oncol. 2016;34(30):3609–3617.
   PubMed Web of Science ®Google Scholar
• Cavo M. A third-generation IMiD for MM. Blood. 2011;18:2931–2932.
   Google Scholar
• Dimopoulos MA, Palumbo A, Corradini P, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128(4):497–503.
   PubMed Web of Science ®Google Scholar
• Moreau P, Weisel KC, Song KW, et al. Relationship of response and survival in patients with relapsed and refractory multiple myeloma treated with pomalidomide plus low-dose dexamethasone in the MM-003 trial randomized phase III trial (NIMBUS). Leuk Lymphoma. 2016;57(12):2839–2847.
   PubMed Web of Science ®Google Scholar
• Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science. 2010;327(5971):1345–1350.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi C, et al. Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide. Blood. 2011;118(18):4771–4779.
   PubMed Web of Science ®Google Scholar
• Higgins JJ, Rosen DR, Loveless JM, et al. A gene for nonsyndromic mental retardation maps to chromosome 3p25-pter. Neurology. 2000;55(3):335–340.
   PubMed Web of Science ®Google Scholar
• Awan FT, Johnson AJ, Lapalombella R, et al. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia. Leuk Lymphoma. 2010;51(1):27–38.
   PubMed Web of Science ®Google Scholar
• Damaj G, Lefrere F, Delarue R, et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia. 2003;17(9):1914–1915.
   PubMed Web of Science ®Google Scholar
• Wu H, Zhao C, Gu K, et al. Thalidomide plus chemotherapy exhibit enhanced efficacy in the clinical treatment of T-cell non-Hodgkin’s lymphoma: a prospective study of 46 cases. Mol Clin Oncol. 2014;2(5):695–700.
   PubMedGoogle Scholar
• Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26(11):2326–2335.
   PubMed Web of Science ®Google Scholar
• Zhu YX, Braggio E, Shi CX, et al. Identification of cereblon binding proteins and relationship with response and survival after IMiDs in multiple myeloma. Blood. 2014;124(4):536–545.
   PubMed Web of Science ®Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305.
   PubMed Web of Science ®Google Scholar
• Lu G, Middleton RE, Sun H, et al. The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science. 2014;343(6168):305–309.
   PubMed Web of Science ®Google Scholar
• Bjorklund CC, Lu L, Kang J, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5(10):e354.
   PubMed Web of Science ®Google Scholar
• Kortüm KM, Mai EK, Hanafiah NH, et al. Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes. Blood. 2016; 128(9):1226–1233.
   PubMed Web of Science ®Google Scholar
• Heintel D, Rocci A, Ludwig H, et al. High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone. Br J Haematol. 2013;161(5):695–700.
   PubMed Web of Science ®Google Scholar
• Schuster SR, Kortuem KM, Zhu YX, et al. The clinical significance of cereblon expression in multiple myeloma. Leuk Res. 2014;38(1):23–28.
   PubMed Web of Science ®Google Scholar
• Bila J, Sretenovic A, Jelicic J, et al. Prognostic significance of the cereblon expression in multiple myeloma patients. Clin Lymphoma Myeloma Leuk. 2016;16(11):610–615.
   PubMed Web of Science ®Google Scholar
• Klimowicz A, Neri P, Belch A, et al. High cereblon protein expression correlates with improved response and survival in myeloma patients treated with lenalidomide. Blood (ASH Annual Meeting Abstracts). 2012;120:931.
   Google Scholar
• Huang SY, Lin CW, Lin HH, et al. Expression of cereblon protein assessed by immunohistochemical staining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma. Ann Hematol. 2014;93(8):1371–1380.
   PubMed Web of Science ®Google Scholar
• Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C, et al. Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma. Leuk Lymphoma. 2019;60(1):180–188.
   Web of Science ®Google Scholar
• Qian X, Dimopoulos MA, Amatangelo M, et al. Cereblon gene expression and correlation with clinical outcomes in patients with relapsed/refractory multiple myeloma treated with pomalidomide: an analysis of STRATUS. Leuk Lymphoma. 2019;60(2):462–470.
   PubMed Web of Science ®Google Scholar
• Sehgal K, Das R, Zhang L, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125(26):4042–4051.
   PubMed Web of Science ®Google Scholar
• Gandhi AK, Mendy D, Waldman M, et al. Measuring cereblon as a biomarker of response or resistance to lenalidomide and pomalidomide requires use of standardized reagents and understanding of gene complexity. Br J Haematol. 2014;164(2):233–244.
   PubMed Web of Science ®Google Scholar
• Thakurta A, Gandhi AK, Waldman MF, et al. Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy. Leukemia. 2014;28(5):1129–1131.
   PubMed Web of Science ®Google Scholar
• Martino A, Sainz J, Buda G, et al. Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). Int J Oncol. 2012;40:625–638.
   PubMed Web of Science ®Google Scholar
• Li J, Ji L. Adjusting multiple testing in multilocus analyses using the eigenvalues of a correlation matrix. Heredity (Edinb). 2005;95(3):221–227.
   PubMed Web of Science ®Google Scholar
• Szudy-Szczyrek A, Mlak R, Szczyrek M, et al. Polymorphisms in the promoter region of the CRBN gene as a predictive factor for the first-line CTD therapy in multiple myeloma patients. Oncotarget. 2018;9(35):24054–24068.
   PubMedGoogle Scholar
• Butrym A, Łacina P, Rybka J, et al. Cereblon and IRF4 variants affect risk and response to treatment in multiple myeloma. Arch Immunol Ther Exp. 2016;64(S1):151–S156.
   PubMedGoogle Scholar
• Butrym A, Rybka J, Łacina P, et al. Polymorphisms within beta-catenin encoding gene affect multiple myeloma development and treatment. Leuk Res. 2015;39(12):1462–1466.
   PubMed Web of Science ®Google Scholar